5.42 (-%)
As of Nov 04, 2024
Source:
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase inhibitors that target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid, palmitate.
Country | United States |
Headquarters | san mateo, california |
Phone Number | (650) 561-8600 |
Industry | manufacturing |
CEO | David Happel |
Website | www.sagimet.com |